Anti-inflammatory Therapy
Anti-inflammatory Therapy - Related Videos
12:50
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
0 Views •
Cited by 1 •
2017
Vascular endothelium tightly controls leukocyte recruitment. Inadequate leukocyte extravasation contributes to human inflammatory diseases. Therefore, searching for novel regulatory elements of endothelial activation is necessary to design improved therapies for inflammatory disorders. Here, we describe a comprehensive methodology to characterize novel endothelial regulators that can modify leukocyte trafficking during inflammation.
01:30
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
0 Views •
2025
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis. Diagnostic studies A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
12:43
On-Chip Endothelial Inflammatory Phenotyping
0 Views •
Cited by 3 •
2012
Microfluidic flow chambers etched by photolithography and fabricated from PDMS are applied to probe functional outcomes associated with EC dysfunction and inflammation. In a representative experiment, the ability of differential shear stress to modulate monocytic cell adhesion to cytokine activated EC monolayers is demonstrated.
08:27
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
0 Views •
Cited by 4 •
2018
Dynamic adhesion of immune cells to the vessel wall is a prerequisite for gut homing. Here, we present a protocol for a functional in vitro assay for the impact analysis of anti-integrin antibodies, chemokines or other factors on the dynamic cell adhesion of human cells using addressin-coated capillaries.
13:21
Antibody Generation: Producing Monoclonal Antibodies Using Hybridomas
0 Views •
2023
Source: Frances V. Sjaastad1,2, Whitney Swanson2,3, and Thomas S. Griffith1,2,3,4 1 Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, MN 55455 2 Center for Immunology, University of Minnesota, Minneapolis, MN 55455 3 Department of Urology, University of Minnesota, Minneapolis, MN 55455 4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455 Polyclonal antibodies are defined as a collection of antibodies directed against...
FAQs
Corticosteroids broadly alter gene expression, which can influence multiple inflammatory pathways at once. Nonsteroidal anti-inflammatory drugs act more specifically on cyclooxygenase enzymes, reducing production of prostaglandins associated with inflammatory symptoms. This mechanistic difference helps explain why clinicians consider both the desired degree of immune suppression and treatment-related risks when selecting anti-inflammatory therapy.
Biologic agents can block specific cytokines, signaling proteins that contribute to inflammation, rather than broadly altering inflammatory activity. This targeted mechanism provides a different therapeutic approach from corticosteroids or nonsteroidal drugs. In medicine, the choice depends on whether focused cytokine blockade is appropriate for the inflammatory or autoimmune disorder and how its infection risk compares with other options.
Treatment selection requires weighing symptom control against disease modification and potential harm. Clinicians consider whether inflammation is excessive or persistent, which inflammatory process is involved, and whether broad or more targeted suppression is suitable. Risks identified in the source include infection, gastrointestinal injury, and other treatment-related effects, so the intended benefit must justify the therapy.
The underlying condition guides the therapeutic decision because inflammatory diseases do not all involve the same clinical problems or immune pathways. Anti-inflammatory therapy is used in arthritis, asthma, inflammatory bowel disease, and autoimmune disorders, but the appropriate treatment must be selected according to the need for symptom relief, disease modification, or control of persistent inflammation.
Treatment may aim to reduce inflammation-driven pain and swelling while also limiting tissue damage caused by excessive or persistent immune activity. In some disorders, the goal extends beyond symptom control to disease modification. Evaluating these distinct outcomes helps clinicians balance immediate relief with longer-term control and the risks associated with suppressing inflammatory or immune activity.
Inflammation can protect tissues, so suppressing it may produce both benefit and harm. A therapy that controls damaging inflammation may also increase susceptibility to infection or cause gastrointestinal injury and other adverse effects. This balance is relevant across conditions such as arthritis, asthma, inflammatory bowel disease, and autoimmune disorders, where treatment decisions must account for competing outcomes.